1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one | 100217-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 4-(2-keto-1-benzimidazolinyl)piperazine；1,3-Dihydro-1-(1-piperazinyl)-2H-benzimidazol-2-one；3-piperazin-1-yl-1H-benzimidazol-2-one
• CAS: 100217-31-0
• 化学式: C₁₁H₁₄N₄O
• 分子量: 218.258
• InChiKey: RPASNIRMODSJPG-UHFFFAOYSA-N

物化性质

• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  47.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-Phenyl-4,5-dihydroisoxazol-5-yl)propanal 、 1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one 在 molecular sieve NaBH(OAc)3 作用下， 以 二氯甲烷 为溶剂， 生成 4-(4-chlorophenyl)-1-[3-(3-phenyl-4,5-dihydroisoxazol-5-yl)propyl]piperidine-4-ol
  参考文献：
  名称：

  Novel 4,5,-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof

  摘要：

  本发明涉及一种具有选择性生物活性的新型4,5-二氢异噁唑基烷基哌嗪衍生物，其在多巴胺D3和D4受体上具有生物活性，表示为以下式（1），以及通过还原胺化反应在还原剂存在下的制备方法，其中R1、R2、R3、R4、R5、R6、X和n与规范中定义的相同。

  公开号：

  US20020107253A1

文献信息

• AROMATIC AMINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND AGENTS CONTAINING THE SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1123918B1

  公开（公告）日：2005-03-09
• Design, synthesis and biological profile of new inhibitors of multidrug resistance associated proteins carrying a polycyclic scaffold
  作者：Alessandra Bisi、Silvia Gobbi、Lucia Merolle、Giovanna Farruggia、Federica Belluti、Angela Rampa、Joseph Molnar、Emil Malucelli、Concettina Cappadone

  DOI：10.1016/j.ejmech.2015.01.004

  日期：2015.3

  Following the identification of a novel polycyclic scaffold, leading to the previously reported potent P-gp modulator 1, a small series of easily affordable derivatives bearing a properly selected nitrogen-containing but-2-ynyl side chain was now synthesized and tested to evaluate the MDR reverting activity on two different experimental models. All compounds proved not to be cytotoxic when tested alone and more potent chemosensitizers than the reference verapamil. Some of them showed remarkable effects in combination with doxorubicin, being able to induce apoptotic cell death due to their reverting activity. In particular, 2a and 2c could be regarded as non-toxic new potential chemosensitizers, being able to interfere with different ABC proteins. Moreover, the intrinsic cytotoxicity of compound 1 could broaden its employment as MDR modulator. These results also seem to confirm the polycyclic core of these compounds as a potential new pharmacophoric carrier in medicinal chemistry. (C) 2015 Elsevier Masson SAS. All rights reserved.
• US6673800B2
  申请人：——

  公开号：US6673800B2

  公开（公告）日：2004-01-06
• US7160887B1
  申请人：——

  公开号：US7160887B1

  公开（公告）日：2007-01-09
• Novel 4,5,-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof
  申请人：——

  公开号：US20020107253A1

  公开（公告）日：2002-08-08

  The present invention relates to a novel 4,5-dihydroisoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D 3 and D 4 receptors represented by the following Formula (1), and its preparation method through reductive amination reaction in the presence of reducing agent, 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X and n are the same as defined in the specification.

  本发明涉及一种具有选择性生物活性的新型4,5-二氢异噁唑基烷基哌嗪衍生物，其在多巴胺D3和D4受体上具有生物活性，表示为以下式（1），以及通过还原胺化反应在还原剂存在下的制备方法，其中R1、R2、R3、R4、R5、R6、X和n与规范中定义的相同。